Skip to content

TO · EDT.TO · MEDICAL - DIAGNOSTICS & RESEARCH

Spectral Medical Inc. (EDT.TO) intrinsic value and stock valuation

$1.03as of 2026-11-21 · Mkt cap 416.65M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Spectral Medical Inc. DCF and intrinsic value

InvestorsCraft values EDT.TO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EDT.TO’s statements →

Spectral Medical Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Toronto, ON M9C 1C2 spectraldx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.44M+3% 5y CAGRd
20112025
Net income
-$-47.69M
20112025
Free cash flow
-$-9.72M
20112025
Total equity
-$-69.72M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.44M$2.29M$1.6M$1.67M$2M
Operating income-$-11.69M-$-12M-$-11.42M-$-8.45M-$-6.66M
Net income-$-47.69M-$-15.4M-$-15.66M-$-11.28M-$-8.79M
EPSd-$-166.05K-$-54.79K-$-56.22K-$-41.8K-$-34.82K
Operating cash flow-$-9.52M-$-8.82M-$-10.72M-$-9.9M-$-8.7M
Capital expenditure-$-200K-$-30K-$-180K-$-30K-$-480K
Free cash flow-$-9.72M-$-8.85M-$-10.91M-$-9.93M-$-9.18M
Total assets$6.1M$5.32M$5.21M$12M$11.6M
Total debt$21.1M$14.9M$8.56M$7.57M$580K
Net debt$17M$11.9M$5.61M-$-1.77M-$-8.31M
Total equity-$-69.72M-$-27.55M-$-16.55M-$-2.55M$4.08M
Cash and short-term investments$4.07M$2.99M$2.95M$8.41M$8.89M
Income statement
20252024202320222021
Revenue$2.44M$2.29M$1.6M$1.67M$2M
Cost of revenue$7.6M$1.27M$940K$680K$830K
Gross profit-$-5.16M$1.02M$660K$980K$1.16M
Research and development expenses$4.33M$3.97M$4.68M$0.00$0.00
Selling, general and administrative expenses$2.19M$11.6M$11.3M$8.64M$7.01M
Other expenses$0.00-$-2.57M$0.00$1.04M$1.04M
Operating expenses$6.53M$13M$12.1M$9.43M$7.86M
Cost and expenses$14.1M$14.3M$13M$10.1M$8.65M
Interest income$5.39M$0.00$0.00$0.00$0.00
Interest expense$5.16M$3.18M$1.33M$180K$30K
Depreciation and amortization$250K$250K$220K$270K$290K
Ebitda-$-11.44M-$-11.97M-$-13.96M-$-7.18M-$-6.38M
Operating income-$-11.69M-$-12M-$-11.42M-$-8.45M-$-6.66M
Total other income/expenses, net-$-36M-$-3.4M-$-4.09M$820K-$-40K
Income before tax-$-47.69M-$-15.39M-$-15.51M-$-7.63M-$-6.96M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-47.69M-$-15.4M-$-15.66M-$-11.28M-$-8.79M
Weighted average shares outstanding$287.2M$281.1M$278.6M$269.8M$252.5M
Weighted average diluted shares outstanding$287.2M$281.1M$278.6M$269.8M$252.5M
Balance sheet
20252024202320222021
Cash and short-term investments$4.07M$2.99M$2.95M$8.41M$8.89M
Net receivables$200K$450K$190K$1.06M$200K
Inventory$380K$230K$370K$340K$290K
Total current assets$5.29M$4.46M$4.12M$10.1M$10.3M
Property, plant and equipment, net$470K$690K$890K$700K$1.06M
Goodwill and intangible assets$330K$170K$190K$210K$230K
Long-term investments$0.00$0.00$0.00$1M$0.00
Total non-current assets$810K$860K$1.09M$1.91M$1.29M
Total assets$6.1M$5.32M$5.21M$12M$11.6M
Accounts payable$1.34M$990K$1.6M$1.65M$440K
Short-term debt$16.6M$14.6M$390K$3.66M$90K
Deferred revenue$690K$380K$730K$700K$690K
Total current liabilities$66.3M$27.5M$10.2M$6.63M$2.3M
Long-term debt$4.52M$370K$8.18M$3.91M$490K
Deferred revenue, non-current$4.56M$5.05M$3.34M$4.01M$4.68M
Total non-current liabilities$9.55M$5.42M$11.5M$7.92M$5.17M
Capital lease obligations$230K$500K$620K$520K$580K
Total liabilities$75.8M$32.9M$21.8M$14.6M$7.47M
Common stock$95.9M$90.6M$87.1M$87.1M$84.4M
Retained earnings-$-188.53M-$-140.84M-$-125.44M-$-109.78M-$-98.49M
Accumulated other comprehensive income (loss)$12.7M$12.6M$12.9M$11.4M$10.2M
Total equity-$-69.72M-$-27.55M-$-16.55M-$-2.55M$4.08M
Total investments$0.00$0.00$0.00$1M$0.00
Total debt$21.1M$14.9M$8.56M$7.57M$580K
Net debt$17M$11.9M$5.61M-$-1.77M-$-8.31M
Cash flow statement
20252024202320222021
Net income$0.00-$-15.39M-$-15.66M-$-11.25M-$-8.79M
Depreciation and amortization$250K$250K$220K$270K$290K
Stock-based compensation$0.00$1.68M$1.49M$1.2M$1.26M
Change in working capital-$-190K$1.01M-$-410K$580K-$-1.76M
Accounts receivable$250K-$-270K$870K-$-880K$60K
Inventory-$-150K$140K-$-30K-$-50K-$-50K
Accounts payable-$-270K-$-50K-$-270K$1.65M-$-1.1M
Net cash provided by operating activities-$-11.63M-$-8.82M-$-10.72M-$-9.9M-$-8.7M
Investments in property, plant and equipment-$-200K-$-30K-$-180K-$-30K-$-480K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-200K-$-30K-$-180K-$-30K-$-330K
Common stock issued$3.4M$1.15M$0.00$4.03M$10M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.9M$8.88M$5.44M$9.46M$12.2M
Net change in cash$1.08M$40K-$-5.46M-$-480K$3.08M
Cash at end of period$4.07M$2.99M$2.95M$8.41M$8.89M
Operating cash flow-$-9.52M-$-8.82M-$-10.72M-$-9.9M-$-8.7M
Capital expenditure-$-200K-$-30K-$-180K-$-30K-$-480K
Free cash flow-$-9.72M-$-8.85M-$-10.91M-$-9.93M-$-9.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Spectral Medical Inc.

        Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

        CEO
        Christopher Seto
        Employees
        29
        Beta
        0.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Spectral Medical Inc. (EDT.TO)?

        InvestorsCraft does not currently publish an intrinsic value for EDT.TO. How the IC value is calculated.

        Is EDT.TO undervalued?

        InvestorsCraft does not publish an undervaluation signal for EDT.TO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.